Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.
about
A review of a family of ultra-rapid-acting insulins: formulation developmentImproved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control.Accelerating and improving the consistency of rapid-acting analog insulin absorption and action for both subcutaneous injection and continuous subcutaneous infusion using recombinant human hyaluronidasePostprandial plasma glucose response and gastrointestinal symptom severity in patients with diabetic gastroparesis.Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming.Ultrafast-acting insulins: state of the artInsulin therapies: Current and future trends at dawn.Moving toward the ideal insulin for insulin pumps.Short acting insulin analogues in intensive care unit patients.Ultra-rapid absorption of recombinant human insulin induced by zinc chelation and surface charge masking.Subcutaneous injection versus subcutaneous infusion of insulin: are the rates of absorption truly the same?Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): a 52-week, randomized, treat-to-target, phase 3 trial.Formulation of two-layer dissolving polymeric microneedle patches for insulin transdermal delivery in diabetic mice.U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
P2860
Q26823197-C7AC8A48-5839-4204-B617-7F7446CAE3A6Q36158995-B6724046-57F4-4924-B5BD-B08BB0F6D2DEQ36229271-BBF80A6E-0452-4418-A5AE-616CCDC17476Q36608939-AE4DE5E2-1E80-4726-A550-9205CA3882B9Q37460129-B1FC9CA4-A227-4847-A8C1-3F66DD009320Q38037727-829B2DA5-A577-4AF5-A609-54D377490FDFQ38089594-4FA48D93-6203-4C28-9B42-3C09C5AEEFC1Q38631154-0497BBA7-997B-4E7C-BFDF-5AB0526E3581Q40743447-9144C2E2-627A-465D-AAEA-1AA8F78F9EB1Q42268809-5F43072E-4C30-432C-A2AA-D7822DF4FE70Q42959127-04999B6A-6401-4BEB-ADD2-2DA2E285D3DCQ47188954-6CFE15AE-286B-478A-BB61-0F3CAD29B27DQ51193134-528CE9BA-B2DA-4ADA-AED0-4217CD556B29Q51367050-77A29E4D-81EA-4B0D-8A46-99723F24CE26
P2860
Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Reduction of postprandial glyc ...... log and regular human insulin.
@ast
Reduction of postprandial glyc ...... log and regular human insulin.
@en
type
label
Reduction of postprandial glyc ...... log and regular human insulin.
@ast
Reduction of postprandial glyc ...... log and regular human insulin.
@en
prefLabel
Reduction of postprandial glyc ...... log and regular human insulin.
@ast
Reduction of postprandial glyc ...... log and regular human insulin.
@en
P2093
P2860
P50
P1476
Reduction of postprandial glyc ...... log and regular human insulin.
@en
P2093
Frank Flacke
Kerstin Albus
Patrick Simms
Solomon Steiner
P2860
P304
P356
10.1177/193229681100500322
P577
2011-05-01T00:00:00Z